Crow Point Partners’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Crow Point Partners’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-260	Closed	-$29K	–	152
2019 Q3	$29K	Sell	260 -53	-17%	-$10.7K	﹤0.01%	125
2019 Q2	$93K	Sell	313 -150	-32%	-$62.6K	0.01%	120
2019 Q1	$208K	Buy	463 +99	+27%	+$43.3K	0.04%	110
2018 Q4	$164K	Sell	364 -7	-2%	-$4.34K	0.03%	112
2018 Q3	$337K	Buy	371 +227	+158%	+$150K	0.06%	104
2018 Q2	$84K	Buy	144 +61	+73%	+$39.8K	0.02%	118
2018 Q1	$54K	Buy	+83	New	+$62.3K	0.01%	194

Other funds holding HTGM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HWM

HighMark Wealth Management St. Paul, Minnesota $299M AUM 53.01% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Crow Point Partners's HTGM Position: Q4 2019 in Review

Crow Point Partners sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2019, closing a stake of 260 shares — an estimated $29K sold.

Crow Point Partners first reported a position in HTGM in Q1 2018 and held it in 7 quarters. The position peaked at $337K in Q3 2018. 27 funds tracked by Wall St. Rank hold HTGM as of Q4 2019.

Crow Point Partners reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Crow Point Partners sold 260 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2019, an estimated $29K.
Crow Point Partners first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2018 and held it in 7 quarters.
Crow Point Partners's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $337K in Q3 2018.
27 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2019.

Based on Crow Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.